Dopamine transporter 3′-UTR VNTR genotype and ADHD:: a pharmaco-behavioural genetic study with methylphenidate

被引:48
作者
Joober, Ridha
Grizenko, Natalie
Sengupta, Sarojini
Ben Amor, Leila
Schmitz, Norbert
Schwartz, George
Karama, Sherif
Lageix, Philippe
Fathalli, Ferid
Torkaman-Zehi, Adam
Ter Stepanian, Marina
机构
[1] Douglas Hosp, Res Ctr, Dept Psychiat, Verdun, PQ H4H 1R3, Canada
[2] McGill Univ, Dept Psychiat, Montreal, PQ H3A 2T5, Canada
[3] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada
[4] McGill Univ, Dept Human Genet, Montreal, PQ H3A 2T5, Canada
[5] Douglas Hosp, Res Ctr, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
attention-deficit; hyperactivity disorder; dopamine transporter; SLC6A3; methylphenidate; pharmacogenetics;
D O I
10.1038/sj.npp.1301240
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We sought to test the hypothesis that the variable number of tandem repeat (VNTR) polymorphism in the 30-untranslated region (30-UTR) of the SLC6A3 gene modulates behavior in children with ADHD and/or behavioral response to methylphenidate (MPH). One hundred and fifty-nine children with AHDH (6-12 years) were assessed with regard to the Conners' Global Index for parents (CGI-Parents) and teachers (CGI- Teachers) and the response of these behaviors to MPH (0.5 mg/kg/day) using a 2-week prospective within-subject (crossover) trial. Based on CGI- Parents, the profile of behavioral response to MPH as compared to placebo was not parallel in the three groups of children separated according to their genotype in the 30-UTR VNTR polymorphism of SLC6A3, as indicated by a significant (p = 0.017) genotype by treatment two-way interaction. Individuals having the 9/10 and 10/10 genotypes displayed a significant positive response to MPH as opposed to those homozygous for the 9-repeat allele. No genotype or genotype by treatment interaction was observed for CGI- Teachers. These findings support a role for the DAT gene 30-UTR VNTR polymorphism in modulating the response of some behavioral dimensions to MPH in children with ADHD. They also suggest the presence of genetic heterogeneity that could be indexed by the quality of behavioral response to MPH.
引用
收藏
页码:1370 / 1376
页数:7
相关论文
共 37 条
[1]  
[Anonymous], 1991, CHILD BEHAV CHECKLIS
[2]   Attention-deficit hyperactivity disorder [J].
Biederman, J ;
Faraone, SV .
LANCET, 2005, 366 (9481) :237-248
[3]  
CONNERS CK, 1999, RITALIN THEORY PRACT, P113
[4]  
Conners CK, 1997, CONNERS RATING SCALE
[5]   Stimulant effects in attention deficit hyperactivity disorder: Theoretical and empirical issues [J].
Denney, CB .
JOURNAL OF CLINICAL CHILD PSYCHOLOGY, 2001, 30 (01) :98-109
[6]   Correspondence of parent and teacher reports in medication trials [J].
Faraone, SV ;
Biederman, J ;
Zimmerman, B .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2005, 14 (01) :20-27
[7]  
Fuke S., 2001, Pharmacogenomics Journal, V1, P152
[8]  
Greenwood TA, 2001, AM J MED GENET, V105, P145, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1161>3.0.CO
[9]  
2-8
[10]   Genotype influences in vivo dopamine transporter availability in human striatum [J].
Heinz, A ;
Goldman, D ;
Jones, DW ;
Palmour, R ;
Hommer, D ;
Gorey, JG ;
Lee, KS ;
Linnoila, M ;
Winberger, DR .
NEUROPSYCHOPHARMACOLOGY, 2000, 22 (02) :133-139